Brilinta tablet

Brilinta tablet®
Black Box Warning
Adult Indications and Dosage
Pediatric Indications and Dosage
Contraindications
Warnings
Adverse Reactions
Drug Interactions
Use in Specific Populations
Routes and Preparations
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient information
Precautions with Alcohol
Look-Alike Drug Names
Drug Shortage Status
Price

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]{{{authorTag}}}

For information about {{{genericName}}}, click here.

Overview

Brilinta tablet is a P2Y12 platelet inhibitor drug that is FDA approved for the treatment of {{{indication}}}. Adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Off-Label Use and Dosage (Adult)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatric Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Routes and Preparations

Routes

Preparations

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Nonclinical Toxicology

Images

Drug Images

Package and Label Display Panel

Black Box Warning

Below is the code to be placed on the Black Box Warning Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}

{{BlackBoxTemplate|blackBoxWarningTitle=WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS|blackBoxWarningBody=A. BLEEDING RISK

• BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.
• Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage.
• Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery.
• Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA.
• If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events.

B. ASPIRIN DOSE AND BRILINTA EFFECTIVENESS

Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day.}}

Use in Specific Populations

Below is the code to be placed on the Drug Interaction Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}

===Pregnancy===

: '''[[Pregnancy category#United States|Pregnancy Category (FDA)]]'''

There is no FDA guidance on usage of {{BASEPAGENAME}} in women who are pregnant.

:'''[[Pregnancy category#Australia|Pregnancy Category (AUS)]]'''

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{BASEPAGENAME}} in women who are pregnant.

===Labor and Delivery===

There is no FDA guidance on use of {{BASEPAGENAME}} during labor and delivery.

===Nursing Mothers===

There is no FDA guidance on the use of {{BASEPAGENAME}} in women who are nursing.

===Pediatric Use===

There is no FDA guidance on the use of {{BASEPAGENAME}} in pediatric settings.

===Geriatic Use===

There is no FDA guidance on the use of {{BASEPAGENAME}} in geriatric settings.

===Gender===

There is no FDA guidance on the use of {{BASEPAGENAME}} with respect to specific gender populations.

===Race===

There is no FDA guidance on the use of {BASEPAGENAME}} with respect to specific racial populations.

===Renal Impairment===

There is no FDA guidance on the use of {{BASEPAGENAME}} in patients with renal impairment.

===Hepatic Impairment===

There is no FDA guidance on the use of {{BASEPAGENAME}} in patients with hepatic impairment.

===Females of Reproductive Potential and Males===

There is no FDA guidance on the use of {{BASEPAGENAME}} in women of reproductive potentials and males.

===Immunocompromised Patients===

There is no FDA guidance one the use of {{BASEPAGENAME}} in patients who are immunocompromised.

{{DrugReflist}}

Overdose

Below is the code to be placed on the Overdose Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}

'''Please contact the National Poison Help hotline (1-800-222-1222) immediately if there is suspicion of drug poisoning or overdose.'''

===Overdose===

{{{overdose}}}

{{DrugReflist}}

Pharmacology

Below is the code to be placed on the Pharmacology Microchapter:

__NOTOC__

{{Labeltemplate}}

{{CMG}}

===Mechanism of Action===

{{{mechAction}}}

===Structure===

{{{structure}}}

===Pharmacodynamics===

{{{PD}}}

===Pharmacokinetics===

{{{PK}}}

===Nonclinical Toxicology===

{{{nonClinToxic}}}

{{DrugReflist}}